title: Multidrug therapy in multibacillary leprosy; experience in an urban leprosy center.
abstract: The article records the experience of treating multibacillary (BB, BL and LL) leprosy with multidrug therapy (MDT) in an urban leprosy center. The problem of leprosy is to be properly assessed throughout the Indian subcontinent because most of the epidemiological data from the areas labeled low-endemic have to be updated. The regularity of therapy must be ensured and monitored constantly, but in spite of our efforts to do so some factors were beyond our control, such as providing a means of livelihood for the migrants from other places. In addition, the intake of drugs also has to be periodically checked from the history and discoloration of skin and, most importantly, confirmed by performing random spot tests for dapsone in the urine. The main problems discussed are the difficulty in demonstrating acid-fast bacilli in slit-skin smears from the macular form of borderline leprosy (also called dimorphous macular) and, secondly, whether the duration of multibacillary therapy was adequate since only approximately 50% of our patients achieved smear negativity after taking MDT for the stipulated period of 24 months. Experiences from other centers have suggested that the duration of MDT should be prolonged in multibacillary patients to achieve smear-negative status. Yet another group notes that smear negativity is gradually achieved during the period of surveillance following stoppage of MDT after 24 months. These questions await more information from good centers with controlled field studies.
authors.affiliation: Department of Dermatology and Leprology, Safdarjang Hospital, New Delhi, India.
authors.forename: V
authors.initials: V
authors.lastname: Ramesh
authors.forename: R S
authors.initials: RS
authors.lastname: Misra
authors.forename: U
authors.initials: U
authors.lastname: Saxena
mesh_terms: D003622:Dapsone / Q000652:urine; D004359:Drug Therapy, Combination; D006801:Humans; D007194:India; D007916:Lepromin; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy*; D010349:Patient Compliance; D014505:Urban Population
chemical_list: D007917:Leprostatic Agents; D007916:Lepromin; D003622:Dapsone